The road to resistance: EGFR mutation and cetuximab

被引：61

作者：

Bardelli, Alberto ^{[1
]}

Jaenne, Pasi A. ^{[2
]}

机构：

[1] Univ Turin, Mol Genet Lab, Inst Canc Res & Treatment, Sch Med, Turin, Italy

[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

NATURE MEDICINE | 2012年 / 18卷 / 02期

关键词：

ACQUIRED-RESISTANCE; PANITUMUMAB;

D O I：

10.1038/nm.2646

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).

引用

页码：199 / 200

页数：2

共 14 条

[11] Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer [J].

Montagut, Clara ;

Dalmases, Alba ;

Bellosillo, Beatriz ;

Crespo, Marta ;

Pairet, Silvia ;

Iglesias, Mar ;

Salido, Marta ;

Gallen, Manuel ;

Marsters, Scot ;

Tsai, Siao Ping ;

Minoche, Andre ;

Somasekar, Seshagiri ;

Serrano, Sergi ;

Himmelbauer, Heinz ;

Bellmunt, Joaquim ;

Rovira, Ana ;

Settleman, Jeff ;

Bosch, Francesc ;

Albanell, Joan .

NATURE MEDICINE, 2012, 18 (02) :221-223

[12] Platinum-based chemotherapy plus cetuximab in head and neck cancer [J].

Vermorken, Jan B. ;

Mesia, Ricard ;

Rivera, Fernando ;

Remenar, Eva ;

Kawecki, Andrzej ;

Rottey, Sylvie ;

Erfan, Jozsef ;

Zabolotnyy, Dmytro ;

Kienzer, Heinz-Roland ;

Cupissol, Didier ;

Peyrade, Frederic ;

Benasso, Marco ;

Vynnychenko, Ihor ;

De Raucourt, Dominique ;

Bokemeyer, Carsten ;

Schueler, Armin ;

Amellal, Nadia ;

Hitt, Ricardo .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (11) :1116-1127

[13]

Yin Ming, 2016, ONCOLOGIST, V21, P708, DOI [10.1634/theoncologist.2015-0440, DOI 10.1634/THEONCOLOGIST.2015-0440]

[14] Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab [J].

Yonesaka, Kimio ;

Zejnullahu, Kreshnik ;

Okamoto, Isamu ;

Satoh, Taroh ;

Cappuzzo, Federico ;

Souglakos, John ;

Ercan, Dalia ;

Rogers, Andrew ;

Roncalli, Massimo ;

Takeda, Masayuki ;

Fujisaka, Yasuhito ;

Philips, Juliet ;

Shimizu, Toshio ;

Maenishi, Osamu ;

Cho, Yonggon ;

Sun, Jason ;

Destro, Annarita ;

Taira, Koichi ;

Takeda, Koji ;

Okabe, Takafumi ;

Swanson, Jeffrey ;

Itoh, Hiroyuki ;

Takada, Minoru ;

Lifshits, Eugene ;

Okuno, Kiyotaka ;

Engelman, Jeffrey A. ;

Shivdasani, Ramesh A. ;

Nishio, Kazuto ;

Fukuoka, Masahiro ;

Varella-Garcia, Marileila ;

Nakagawa, Kazuhiko ;

Jaenne, Pasi A. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (99)

← 1 2 →